NCT00226421已完成3 期
An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Experienced Patients With Chronic Low Back Pain
Endo Pharmaceuticals60 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2004年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 60
- 主要终点
- Change in pain intensity from baseline (pre-randomization) to last assessment.
研究概览
简要总结
The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in opioid-experienced patients with chronic low back pain.
详细描述
Patients with chronic low back pain on stable opioid treatment will be converted to oxymorphone extended release (ER)and enter an open-label treatment phase.During the Open-Label Titration Period (up to 28 days), patients will receive daily oxymorphone ER PO q12h. Patients stabilized on a dose that provides adequate pain relief will be randomized to either continue on the stabilized dose of oxymorphone ER or receive placebo in a double-blind fashion for a total duration of 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females 18 years of age or older
- •In good health as determined by the Investigator on the basis of medical history and physical examination.
- •Moderate to severe chronic non-neuropathic low back pain that has been present daily for at least several hours per day for a minimum of three months prior to the screening.
- •On a stable around-the-clock opioid pain medication for the management of moderate to severe chronic lower back pain.
- •Expected to require a total daily oxymorphone ER dose that is a minimum of 20 mg per day (oral morphine equivalent: approximately 60 mg) and will not exceed 220 mg oxymorphone ER (oral morphine requirement: approximately 660 mg).
- •Any adjunct therapy for back pain such as physical therapy, biofeedback therapy, acupuncture therapy or herbal remedies, based on the patient's current status should remain unchanged during the period of participation of the patient.
- •Written informed consent
排除标准
- •Pregnant and/or lactating
- •Subjects with radiculopathy, fibromyalgia, reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, severe lower extremity weakness or numbness, bowel or bladder dysfunction secondary to cauda equina compression, diabetic amyotrophy, meningitis, discitis, or back pain due to secondary infection or tumor.
- •Cannot or will not agree to stop local regional pain treatments during the study (nerve/plexus blocks or ablation, neurosurgical procedures for pain control, Botulinum toxin injections, or inhalation analgesia). The patient must not have a nerve/plexus block within 4 weeks of screening (Visit 1). The patient must not have a Botulinum toxin injection in the lower back region within 3 months of screening.
- •Intend to alter their physical therapy regimen during the study.
- •Surgical procedures directed towards the source of back pain within 6 months of screening.
- •Pain which is secondary to confirmed or suspected neoplasm.
- •Dysphagia or difficulty swallowing tablets or capsules.
- •Significant prior history of substance abuse or alcohol abuse.
- •Use of any investigational medication within 30 days prior to the first dose of study medication.
- •Previous exposure to oxymorphone.
- •History of clinically significant intolerance to oxymorphone or a known hypersensitivity to opioid analgesics.
- •History of seizure.
- •use of MAO inhibitor within 14 days prior to the start of study medication.
- •Other clinically significant conditions as judged by the investigator.
结局指标
主要结局
Change in pain intensity from baseline (pre-randomization) to last assessment.
次要结局
- - Physician's Global Assessment of Pain Medication
- - Pain Quality Assessment Scale
- - Patient's Global Assessment of Pain Medication
- - Safety as measured by AEs
- - Time to early discontinuation due to lack of efficacy
研究者
研究点 (60)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant PainChronic PainNCT00225797Endo Pharmaceuticals160
已完成
3 期
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsPost Operative PainNCT01210352Endo Pharmaceuticals61
已完成
3 期
Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic EfficacyCancers, PainLower Back PainNCT00904280Endo Pharmaceuticals239
撤回
3 期
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric SubjectsChronic PainNCT01206907Endo Pharmaceuticals
已完成
3 期
Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute PainAcute PainNCT00226395Endo Pharmaceuticals320